loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Sun Pharmaceutical Industries has received USFDA approval for ILUMYA

ICICIdirect Research 30 Oct 2026 DISCLAIMER

News: Sun Pharmaceutical Industries has received USFDA approval for ILUMYA (tildrakizumab-asmn) for treating adults with active psoriatic arthritis (PsA). The approval expands the drug’s use beyond moderate-to-severe plaque psoriasis, for which it was approved in the US in 2018. ILUMYA is an IL-23 inhibitor administered exclusively by healthcare professionals, offering an option for patients unable to self-administer treatment or those who may benefit from in-office care. The approval is supported by two Phase III studies, INSPIRE-1 and INSPIRE-2, evaluating efficacy and safety in adults with active PsA. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in India, Australia, Canada, China and Japan, and under the brand name ILUMETRI in Europe, where it is marketed by Almirall.

View: Approval for additional indication is a significant development and could pave way for incremental revenues. Approximately 2.4 million Americans live with psoriatic arthritis. As per earlier comments from the management. ~30% of the patients with plaque psoriasis are likely to get impacted by psoriatic arthritis as well in the due course. We will get some insights from the management.

Impact: Positive

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere